Mikofenolsav Tillomed (Mycophenolic Acid)

Mycophenolic acid blocks the enzyme inosine monophosphate dehydrogenase, which is essential for making guanosine nucleotides. This inhibition limits the proliferation of activated T and B lymphocytes, thereby reducing the immune response that can damage transplanted tissue or inflamed kidneys.

The specific dose of Mikofenolsav Tillomed is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

The safety of mycophenolic acid in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their physician before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mycophenolic acid differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcium‑dependent signaling. This distinct mechanism can offer a complementary safety profile, but the choice of therapy depends on the transplant protocol, patient tolerance and physician judgment.

Store Mikofenolsav Tillomed at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed when not in use.

Mikofenolsav Tillomed is taken orally, usually with food or a glass of water to improve tolerability. The exact administration schedule, including timing relative to other medications, should follow the prescribing clinician’s instructions.

Serious risks include severe bone‑marrow suppression (e.g., neutropenia, agranulocytosis), opportunistic infections such as Pneumocystis jirovecii pneumonia, and potential liver toxicity. Patients should be monitored regularly for blood count changes and signs of infection.

Mikofenolsav Tillomed is contraindicated in patients with known hypersensitivity to mycophenolic acid or any of its excipients, in those with active uncontrolled infections, and in individuals with severe renal impairment unless dose adjustments are made under medical supervision.